Profile data is unavailable for this security.
About the company
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
- Revenue in USD (TTM)358.00m
- Net income in USD60.76m
- Incorporated1998
- Employees644.00
- LocationCareDx Inc8000 Marina Blvd, 4Th FloorBRISBANE 94005United StatesUSA
- Phone+1 (415) 287-2300
- Fax+1 (302) 636-5454
- Websitehttps://www.caredx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aktis Oncology Inc | 5.56m | -60.65m | 906.63m | -- | -- | -- | -- | 163.06 | -1.20 | -1.20 | 0.1098 | 3.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,090.81 | -- | -- | -- | 0.00 | -- | -- | -- | -53.56 | -- | -- | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 913.47m | -- | 57.21 | 1.42 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 920.03m | 119.00 | 13.49 | 8.35 | 31.40 | 8.10 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| Arrivent Biopharma Inc | 0.00 | -151.40m | 925.53m | 52.00 | -- | 3.00 | -- | -- | -4.24 | -4.24 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -48.90 | -- | -51.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.09 | -- | -- | -- |
| GH Research PLC | 0.00 | -42.92m | 931.06m | 50.00 | -- | 3.20 | -- | -- | -0.7313 | -0.7313 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -17.11 | -12.39 | -17.83 | -12.66 | -- | -- | -- | -- | -- | -- | 0.002 | -- | -- | -- | -9.48 | -- | -- | -- |
| Fortrea Holdings Inc | 2.76bn | -1.03bn | 948.95m | 14.50k | -- | 1.63 | -- | 0.3438 | -11.38 | -11.24 | 30.33 | 6.30 | 0.8617 | -- | 4.08 | 178,058.10 | -32.08 | -- | -43.77 | -- | 18.61 | -- | -37.23 | -- | -- | -0.5534 | 0.6598 | -- | -5.14 | -- | -756.47 | -- | -- | -- |
| Palvella Therapeutics Inc | 0.00 | -35.07m | 970.83m | 14.00 | -- | 23.51 | -- | -- | -3.83 | -3.83 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -80.19 | -31.18 | -96.21 | -43.15 | -- | -- | -- | -122.22 | -- | -3.05 | 0.2929 | -- | -100.00 | -- | 28.97 | -- | -- | -- |
| CareDx Inc | 358.00m | 60.76m | 982.36m | 644.00 | 23.71 | 3.16 | 13.05 | 2.74 | 0.8055 | 0.8055 | 6.15 | 6.05 | 0.7874 | 4.87 | 6.25 | 555,897.50 | 13.37 | -11.64 | 16.67 | -13.85 | 67.62 | 66.00 | 16.97 | -18.51 | 2.75 | -- | 0.00 | -- | 19.07 | 21.31 | 127.62 | -- | 14.13 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -135.27m | 997.27m | 106.00 | -- | 2.45 | -- | -- | -1.73 | -1.73 | 0.00 | 4.18 | 0.00 | -- | -- | 0.00 | -36.90 | -36.70 | -39.10 | -38.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.96 | -- | 9.12 | -- |
| Ventyx Biosciences Inc | 0.00 | -106.61m | 999.63m | 83.00 | -- | 5.19 | -- | -- | -1.50 | -1.50 | 0.00 | 2.68 | 0.00 | -- | -- | 0.00 | -41.60 | -50.81 | -43.60 | -53.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.97 | -- | -- | -- |
| Iovance Biotherapeutics Inc | 250.43m | -397.63m | 1.00bn | 838.00 | -- | 1.38 | -- | 3.99 | -1.20 | -1.20 | 0.7552 | 1.82 | 0.2642 | 4.22 | 4.09 | 298,836.50 | -41.94 | -50.14 | -48.13 | -56.84 | 23.96 | -- | -158.78 | -1,097.64 | 3.00 | -- | 0.0014 | -- | 13,698.99 | -- | 16.18 | -- | 9.86 | -- |
| Sana Biotechnology Inc | 0.00 | -234.41m | 1.01bn | 194.00 | -- | 5.09 | -- | -- | -0.9708 | -0.9708 | 0.00 | 0.7447 | 0.00 | -- | -- | 0.00 | -47.13 | -39.42 | -51.39 | -43.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.82 | -- | 5.06 | -- |
| Geron Corp | 183.40m | -79.99m | 1.04bn | 229.00 | -- | 4.18 | -- | 5.67 | -0.1202 | -0.1202 | 0.2754 | 0.3896 | 0.3623 | 0.073 | 5.79 | 800,886.40 | -15.80 | -47.39 | -20.34 | -60.65 | 97.70 | -- | -43.61 | -871.15 | 4.87 | -4.25 | 0.4999 | -- | 32,386.92 | 178.45 | 5.19 | -- | 10.49 | -- |
| Vir Biotechnology Inc | 16.86m | -499.65m | 1.07bn | 408.00 | -- | 1.35 | -- | 63.62 | -3.62 | -3.62 | 0.1223 | 5.73 | 0.0134 | -- | -- | 41,323.53 | -39.69 | -4.58 | -42.97 | -5.34 | 95.94 | -- | -2,963.54 | -13.27 | -- | -- | 0.00 | -- | -13.90 | 55.77 | 15.14 | -- | -3.97 | -- |
Data as of Feb 13 2026. Currency figures normalised to CareDx Inc's reporting currency: US Dollar USD
47.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 4.12m | 8.01% |
| BAMCO, Inc.as of 30 Sep 2025 | 3.16m | 6.14% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.01m | 5.85% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 2.57m | 4.99% |
| Ophir Asset Management Pty Ltd.as of 30 Sep 2025 | 2.20m | 4.27% |
| Braidwell LPas of 30 Sep 2025 | 2.18m | 4.24% |
| ARK Investment Management LLCas of 30 Sep 2025 | 2.17m | 4.22% |
| Amova Asset Management Americas, Inc.as of 30 Sep 2025 | 1.74m | 3.38% |
| Gagnon Securities LLCas of 30 Sep 2025 | 1.73m | 3.36% |
| Amova Asset Management Co., Ltd.as of 31 Dec 2025 | 1.45m | 2.81% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
